Systematic (IUPAC) name
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)- 3,5,10,12,12a-pentahydroxy- 6-methyl- 1,11-dioxo- 1,4,4a,5,5a,6,11,12a-octahydrotetracene- 2-carboxamide
Clinical data
Trade names Doryx, Doxyhexal, Doxylin among others
Licence data US FDA:
  • AU: D
  • US: D (Evidence of risk)
Legal status
Routes of
by mouth, intravenous[1]
Pharmacokinetic data
Bioavailability 100%
Protein binding 90%
Metabolism Hepatic
Biological half-life 15–25 hours
Excretion Urine (40%)
CAS Registry Number  Y
ATC code J01 A01
PubChem CID:
DrugBank  Y
ChemSpider  Y
Chemical data
Formula C22H24N2O8
Molecular mass 444.43 g/mol

Doxycycline is an health system.[4] Doxycycline is available as a generic medicine and is inexpensive.[1][5] The wholesale cost in much of the world is between 0.01 and 0.04 USD per pill.[6] In the United States 10 days of treatment is about 14 USD, however some in 2014 were selling it for more than three to ten USD per pill.[1][7]


  • Medical uses 1
    • Antiprotozoal 1.1
    • Antibacterial 1.2
    • Antihelminthic 1.3
    • Spectrum of susceptibility 1.4
  • Adverse effects 2
    • Interactions 2.1
    • Pregnancy and lactation 2.2
  • Pharmacokinetics 3
  • Physical and chemical properties 4
  • History 5
  • Society and culture 6
    • Brand names 6.1
    • Cost 6.2
  • Research 7
  • References 8
  • External links 9

Medical uses

Generic 100 mg doxycycline capsules

In addition to the general indications for all members of the tetracycline antibiotics group, doxycycline is frequently used to treat Lyme disease, chronic prostatitis, sinusitis, pelvic inflammatory disease,[8][9] acne, rosacea,[10][11] and rickettsial infections.[12]


It is used in prophylaxis against malaria. It should not be used alone for initial treatment of malaria, even when the parasite is doxycycline-sensitive, because the antimalarial effect of doxycycline is delayed. This delay is related to its mechanism of action, which is to specifically impair the progeny of the apicoplast genes, resulting in their abnormal cell division.[13]

It can be used in a treatment plan in combination with other agents, such as quinine.[14]


Moraxella catarrhalis, Brucella melitensis, Chlamydia pneumoniae, and Mycoplasma pneumoniae are generally susceptible to doxycycline, while some Haemophilus spp., Mycoplasma hominis, and Pseudomonas aeruginosa have developed resistance to varying degrees.[15]

It is used in the treatment and prophylaxis of anthrax (caused by Bacillus anthracis) and Leptospirosis.[16] It is also effective against Yersinia pestis (the infectious agent of bubonic plague), and is prescribed for the treatment of Lyme disease,[17][18][19][20] ehrlichiosis[21][22] and Rocky Mountain spotted fever. In fact, because doxycycline is one of the few medications shown to be effective in treating Rocky Mountain spotted fever (with the next-best alternative being chloramphenicol), doxycycline is indicated even for use in children for this illness. Otherwise, it is not indicated for use in children under the age of eight years.

Doxycycline is indicated for treatment of:[23][24]

  • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever,[25] rickettsialpox, and tick fevers caused by Rickettsia
  • Respiratory tract infections caused by Mycoplasma pneumoniae[26]
  • Lymphogranuloma venereum, trachoma, inclusion conjunctivitis, and uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis
  • Psittacosis (ornithosis) caused by Chlamydia psittaci
  • Nongonococcal urethritis caused by Ureaplasma urealyticum
  • Relapsing fever due to Borrelia recurrentis
  • Chancroid caused by Haemophilus ducreyi
  • Plague due to Yersinia pestis
  • Tularemia due to Francisella tularensis
  • Cholera caused by Vibrio cholerae
  • Campylobacter fetus infections
  • Brucellosis caused by Brucella species (in conjunction with streptomycin)
  • Bartonellosis caused by Bartonella bacilliformis
  • Granuloma inguinale caused by Calymmatobacterium granulomatis

When bacteriologic testing indicates appropriate susceptibility to the drug, doxycycline may be used to treat these infections caused by Gram-negative bacteria:[23][24]

Some Gram-positive bacteria have developed resistance to doxycycline. Up to 44% of Streptococcus pyogenes and up to 74% of S. faecalis specimens have developed resistance to the tetracycline group of antibiotics. When bacteriologic testing indicates appropriate susceptibility to the drug, doxycycline may be used to treat these infections caused by Gram-positive bacteria:[23][24]

Doxycycline package

When penicillin is contraindicated, doxycycline can be used to treat:[23][24]

  • Syphilis caused by Treponema pallidum
  • Yaws caused by Treponema pertenue
  • Listeriosis due to Listeria monocytogenes
  • Vincent's infection caused by Fusobacterium fusiforme
  • Actinomycosis caused by Actinomyces israelii
  • Infections caused by Clostridium species.

Doxycycline may also be used as adjunctive therapy for severe acne.[23][24]

The first-line for treatment brucellosis is combination of doxycycline and streptomycin and the second-line is combination of Doxyxycline and rifampin (rifampicin).[27]


Doxycycline kills the symbiotic Wolbachia bacteria in the reproductive tracts of parasitic filarial nematodes, making the nematodes sterile, and thus reducing transmission of diseases such as onchocerciasis and elephantiasis.[28] Field trials in 2005 showed an eight-week course of doxycycline almost completely eliminates the release of microfilariae.[29]

Spectrum of susceptibility

Doxycycline has been used successfully to treat sexually transmitted, respiratory, and ophthalmic infections. Representative pathogenic genera include Chlamydia, Streptococcus, Ureaplasma, Mycoplasma, and others. The following represents MIC susceptibility data for a few medically significant microorganisms.

  • Chlamydia psittaci: 0.03 μg/ml
  • Mycoplasma pneumoniae: 0.016 μg/ml – 2 μg/ml
  • Streptococcus pneumoniae: 0.06 μg/ml – 32 μg/ml[30]

Adverse effects

Cautions and side effects are similar to those of other members of the tetracycline antibiotic group.

An erythematous rash in sun-exposed parts of the body has been reported to occur in 7.3–21.2% of persons taking doxycycline for malaria prophylaxis. One study examined the tolerability of various malaria prophylactic regimens and found doxycycline did not cause a significantly higher percentage of all skin events (photosensitivity not specified) when compared with other antimalarials. The rash resolves upon discontinuation of the drug.[31]

Unlike some other members of the tetracycline group, it may be used in those with renal impairment.[32] Doxycycline is contraindicated in the pediatric treatment of acute bacterial rhinosinusitis.


The combination of doxycycline with dairy, antacids, calcium supplements, iron products, and laxatives containing magnesium is not inherently dangerous, but any of these foods and supplements may decrease doxycycline's effectiveness.[33]

Previously, doxycycline was believed to impair the effectiveness of many types of hormonal contraception due to CYP450 induction. Recent research has shown no significant loss of effectiveness in oral contraceptives while using most tetracycline antibiotics (including doxycycline), although many physicians still recommend the use of barrier contraception for people taking the drug to prevent unwanted pregnancy.[34][35][36]

Pregnancy and lactation

Doxycycline is categorized by the FDA as a class D drug in pregnancy. As with all tetracycline antibiotics, it is contraindicated in pregnancy through infancy and childhood up to eight years of age, due to the potential for disrupting bone and tooth development.[37] Therefore, doxycycline should not be administered to children under the age of eight except in the treatment of anthrax, or where other medications are contraindicated or ineffective.[23]

Doxycycline crosses into breastmilk. The adverse effects on teeth and long bones of children directly administered tetracycline antibiotics is documented, but these effects have not been recorded in infants exposed through breastmilk. Although the dose an infant would receive through breastfeeding would likely be minimal, a theoretical risk exists.[38]


Doxycycline–metal ion complexes are unstable at acid pH, therefore more doxycycline enters the duodenum for absorption compared with the earlier tetracycline compounds. In addition, food has less effect on absorption than on absorption of earlier drugs with doxycycline serum concentrations being reduced by about 20% by test meals compared with 50% for tetracycline.[39]

Physical and chemical properties

Expired tetracyclines or tetracyclines allowed to stand at a pH less than 2 are reported to be nephrotoxic due to the formation of a degradation product, anhydro-4-epitetracycline[40][41] causing Fanconi syndrome.[42] In the case of doxycycline, the absence of a hydroxyl group in C-6 prevents the formation of the nephrotoxic compound.[41] Nevertheless, tetracyclines and doxycycline itself have to be taken with precaution in patients with kidney injury, as they can worsen azotemia due to catabolic effects.[42]


After penicillin revolutionized the treatment of bacterial infections in WWII, many chemical companies moved into the field of discovering antibiotics by bioprospecting. American Cyanamid was one of these, and in the late 1940s chemists there discovered chlortetracycline, the first member of the tetracycline class of antibiotics.[43] Shortly thereafter, scientists at Pfizer discovered terramycin and it was brought to market. Both compounds, like penicillin, were natural products and it was commonly believed that nature had perfected them, and further chemical changes could only degrade their effectiveness. Scientists at Pfizer led by Lloyd Conover modified these compounds, which led to the invention of tetracycline itself, the first semi-synthetic antibiotic. Charlie Stephens at Pfizer worked on further analogs and created one with greatly improved stability and pharmacological efficacy: doxycycline. It was clinically developed in the early 1960s and approved by the FDA in 1967.[43]

As its patent grew near to expiring in the early 1970s, the patent became the subject of lawsuit between Pfizer and International Rectifier[44] that wasn't resolved until 1983; at the time it was the largest litigated patent case in US history.[45] Instead of a cash payment for infringement, Pfizer took the veterinary and feed-additive businesses of International Rectifier's subsidiary, Rachelle Laboratories.[45]

In January 2013, the FDA reported shortages of some, but not all, forms of doxycyline "caused by increased demand and manufacturing issues".[46] Companies involved included an unnamed major generics manufacturer that ceased production in February 2013, Teva (which ceased production in May 2013), Mylan, Actavis, and Hikma Pharmaceuticals.[47][48] The shortage came at a particularly bad time, since there were also shortages of an alternative antibiotic, tetracycline, at the same time.[49] The market price for doxycycline dramatically increased in the United States in 2013 and early 2014 (from $20 to over $1800 for a bottle of 500 tablets),[50][51][52] before decreasing again.[53][54]

Society and culture

Brand names

Doxycycline is available worldwide under many brand names.[55] Brand names include Vibramycin, Monodox, Doryx,[56] Vibrox, Adoxa, Doxyhexal and Atridox (topical doxycycline hyclate for periodontitis).


Doxycycline is available as a generic medicine and is inexpensive.[1][5] The wholesale cost is between 0.01 and 0.04 USD per pill.[6]


Tet-ON inducible shRNA system

At subantimicrobial doses, doxycycline is an inhibitor of cell cultures.

Other experimental applications include treating:


  1. ^ a b c d e f g h "Doxycycline calcium". The American Society of Health-System Pharmacists. Retrieved Aug 18, 2015. 
  2. ^ Nelson, ML; Levy, SB (December 2011). "The history of the tetracyclines.". Annals of the New York Academy of Sciences 1241: 17–32.  
  3. ^ Corey, E.J. (2013). Drug discovery practices, processes, and perspectives. Hoboken, N.J.: John Wiley & Sons. p. 406.  
  4. ^ "WHO Model List of Essential Medicines" (PDF). World Health Organization. April 2015. Retrieved 2 June 2015. 
  5. ^ a b Hamilton, Richard J. (2011). Tarascon pharmacopoeia (2011 library ed., 2011 ed., 12th ed. ed.). Sudbury, MA: Jones & Bartlett Learning. p. 79.  
  6. ^ a b "Doxycycline". International Drug Price Indicator Guide. Retrieved 18 August 2015. 
  7. ^ "Officials Question the Rising Costs of Generic Drugs". New York Times. Oct 7, 2014. Retrieved 22 September 2015. 
  8. ^ Sweet RL, Schachter J, Landers DV, Ohm-Smith M, Robbie MO (1988). "Treatment of hospitalized patients with acute pelvic inflammatory disease: comparison of cefotetan plus doxycycline and ana doxycycline". Am. J. Obstet. Gynecol. 158 (3 Pt 2): 736–41.  
  9. ^ Gjønnaess H, Holten E (1978). "Doxycycline (Vibramycin) in pelvic inflammatory disease". Acta Obstet Gynecol Scand 57 (2): 137–9.  
  10. ^ Määttä M; Kari O; Tervahartiala T; et al. (2006). "Tear fluid levels of MMP-8 are elevated in ocular rosacea—treatment effect of oral doxycycline". Graefes Arch. Clin. Exp. Ophthalmol. 244 (8): 957–62.  
  11. ^ Quarterman MJ, Johnson DW, Abele DC, Lesher JL, Hull DS, Davis LS (1997). "Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline". Arch Dermatol 133 (1): 49–54.  
  12. ^ Walker DH, Paddock CD, Dumler JS (November 2008). "Emerging and re-emerging tick-transmitted rickettsial and ehrlichial infections". Med. Clin. North Am. 92 (6): 1345–61, x.  
  13. ^ Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ (2006). "Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum". Antimicrob. Agents Chemother. 50 (9): 3124–31.  
  14. ^ Lalloo DG; Shingadia D; Pasvol G; et al. (February 2007). "UK malaria treatment guidelines". J. Infect. 54 (2): 111–21.  
  15. ^ "Doxycycline spectrum of bacterial susceptibility and Resistance" (PDF). Retrieved 4 May 2012. 
  16. ^
  17. ^ Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP (1992). "Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease". Annals of Internal Medicine 117 (4): 273–80.  
  18. ^ Luger SW; Paparone P; Wormser GP; et al. (March 1995). "Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans". Antimicrob. Agents Chemother. 39 (3): 661–7.  
  19. ^ Nadelman RB; Nowakowski J; Fish D; et al. (2001). "Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite". N. Engl. J. Med. 345 (2): 79–84.  
  20. ^ Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B (1994). "Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis". Neurologe 44 (7): 1203–7.  
  21. ^ Weinstein RS (1996). "Human ehrlichiosis". Am Fam Physician 54 (6): 1971–6.  
  22. ^ Karlsson U, Bjöersdorff A, Massung RF, Christensson B (2001). "Human granulocytic ehrlichiosis—a clinical case in Scandinavia". Scand. J. Infect. Dis. 33 (1): 73–4.  
  23. ^ a b c d e f U.S. Food and Drug Administration. 14 December 2012. Doxycycline, ANDA no. 065055 Label.
  24. ^ a b c d e U.S. Food and Drug Administration. 16 July 2008.Doxycycline, ANDA no. 065454 Label
  25. ^ Anderson A, Bijlmer H, Fournier PE, Graves S, Hartzell J, Kersh GJ, Limonard G, Marrie TJ, Massung RF, McQuiston JH, Nicholson WL, Paddock CD, Sexton DJ. 2013. "Diagnosis and management of Q fever—United States, 2013: recommendations from CDC and the Q Fever Working Group." MMWR Recomm Rep. 62(RR-03):1–30. PMID 23535757
  26. ^ Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, Chiba N, Iwata S, Ubukata K. 2012. "Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children." Clin Infect Dis. 55(12):1642-9. PMID 22972867
  27. ^ William Cameron. "Comparison of doxycycline–streptomycin, doxycycline–rifampin, and ofloxacin–rifampin in the treatment of brucellosis: a randomized clinical trial". Retrieved 23 August 2014. 
  28. ^ Hoerauf A; Mand S; Fischer K; et al. (2003). "Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production". Med. Microbiol. Immunol. 192 (4): 211–6.  
  29. ^ Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A (2005). "Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial". Lancet 365 (9477): 2116–21.  
  30. ^
  31. ^ Center for Global Health, Centers for Disease Control and Prevention (2011). "Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis".  
  32. ^ Center for Drug Evaluation and Research (November–December 2004). "European recommendations on the use of oral antibiotics for acne".  
  33. ^ National Center for Biotechnology Information (September 2010). "AHFS Consumer Medication Information".  
  34. ^ Archer JS, Archer DF (2002). "Oral contraceptive efficacy and antibiotic interaction: a myth debunked". J. Am. Acad. Dermatol. 46 (6): 917–23.  
  35. ^ Dréno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H (November–December 2004). "European recommendations on the use of oral antibiotics for acne" (PDF). Eur J Dermatol 14 (6): 391–9.  
  36. ^ DeRossi SS, Hersh EV (2002). "Antibiotics and oral contraceptives". Dent. Clin. North Am. 46 (4): 653–64.  
  37. ^ Mylonas, I (January 2011). "Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration.". Archives of gynecology and obstetrics 283 (1): 7–18.  
  38. ^ Chung, AM; Reed, MD; Blumer, JL (2002). "Antibiotics and breast-feeding: a critical review of the literature.". Paediatric drugs 4 (12): 817–37.  
  39. ^ Agwuh, KN, MacGowan, A (2006). "Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines". J. Antimicrob. Chemother. 58 (2): 256–265.  
  40. ^ "Principles and methods for the assessment of nephrotoxicity associated with exposure to chemicals". Environmental health criteria: 119. World Health Organization (WHO). ISBN 92-4-157119-5. ISSN 0250-863X. 1991.
  41. ^ a b Foye's Principles of Medicinal Chemistry; David A. Williams; William O. Foye, Thomas L. Lemke
  42. ^ a b Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12ed, Laurence L. Brunton, Bruce A. Chabner, Björn C. Knollmann
  43. ^ a b Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci. 2011 Dec;1241:17–32 PMID 22191524
  44. ^ Pfizer, Inc. v. International Rectifier Corp., 545 F. Supp. 486 (C.D. Cal. 1980)
  45. ^ a b The Associated Press, 6 July 1983 Pfizer to Get Rachelle Units The New York Times.
  46. ^ CDC Health Alert Network 12 June 2013 Nationwide Shortage of Doxycycline: Resources for Providers and Recommendations for Patient Care
  47. ^ American Society of Health-System Pharmacists. 12 December 2014 Doxycycline Capsules and Tablets
  48. ^ American Society of Health-System Pharmacists. 12 November 2014 Doxycycline Hyclate Injection
  49. ^ Consumer Reports News: 4 February 2013 FDA reports shortage of doxycycline antibiotic. What are your options?
  50. ^ Sudden increase in cost of common drug concerns many, WSMV-TV, 12 March 2013 (updated 26 March 2013).
  51. ^ Rosenthal, Elisabeth, Officials Question the Rising Costs of Generic Drugs, The New York Times, 7 October 2014.
  52. ^ Eric Palmer for FiercePharmaManufacturing. 13 March 2014 Hikma hits the jackpot with doxycycline shortage
  53. ^ "Costco Drug Information". n.d. 
  54. ^ "Doxycycline Hyclate Prices and Doxycycline Hyclate Coupons". GoodRx. n.d. Retrieved n.d. 
  55. ^ international availability for doxycycline Page accessed April 29, 2015
  56. ^ Voreacos, David; Decker, Susan (30 April 2012). "Mylan, Impax Win Ruling in Doryx Generics Patent Case". Bloomberg. 
  57. ^ Dursun D, Kim MC, Solomon A, Pflugfelder SC (2001). "Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids". Am. J. Ophthalmol. 132 (1): 8–13.  
  58. ^ Duivenvoorden, W. C.; Hirte, H. W.; Singh, G. (1997). "Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells". Invasion & metastasis 17 (6): 312–322.  
  59. ^ Fife, R. S.; Sledge Jr, G. W. (1995). "Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells". The Journal of laboratory and clinical medicine 125 (3): 407–411.  
  60. ^ Duivenvoorden, W. C.; Popović, S. V.; Lhoták, S.; Seidlitz, E.; Hirte, H. W.; Tozer, R. G.; Singh, G. (2002). "Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer". Cancer research 62 (6): 1588–1591.  
  61. ^ Moses MA, Harper J, Folkman J (2006). "Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs". N. Engl. J. Med. 354 (24): 2621–2.  
  62. ^ Errami M, Galindo CL, Tassa AT, Dimaio JM, Hill JA, Garner HR (2007). "Doxycycline attenuates isoproterenol- and transverse aortic banding- induced cardiac hypertrophy in mice". J Pharmacol Exp Ther 324 (3): 1196–203.  
  63. ^ Dalvi PS; Singh A; Trivedi HR; et al. (2011). "Effect of doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptoms". Ann Thorac Med 6 (4): 221–6.  
  64. ^ Saraiva IH, Jones RN, Erwin M, Sader HS (1997). "[Evaluation of antimicrobial sensitivity of 87 clinical isolates of vancomycin-resistant enterococci]". Rev Assoc Med Bras (in Portuguese) 43 (3): 217–22.  
  65. ^ Dibb WL, Digranes A (1981). "Characteristics of 20 human Pasteurella isolates from animal bite wounds". Acta Pathol Microbiol Scand [B] 89 (3): 137–41.  
  66. ^ Greenwald RA (December 2011). "The road forward: the scientific basis for tetracycline treatment of arthritic disorders". Pharmacol. Res. 64 (6): 610–3.  
  67. ^ Raza M, Ballering JG, Hayden JM, Robbins RA, Hoyt JC (2006). "Doxycycline decreases monocyte chemoattractant protein-1 in human lung epithelial cells". Exp. Lung Res. 32 (1–2): 15–26.  
  68. ^ Chodosh S, Tuck J, Pizzuto D (1988). "Comparative trials of doxycycline versus amoxicillin, cephalexin and enoxacin in bacterial infections in chronic bronchitis and asthma". Scand J Infect Dis Suppl 53: 22–8.  
  69. ^ Joks R, Durkin HG (December 2011). "Non-antibiotic properties of tetracyclines as anti-allergy and asthma drugs". Pharmacol. Res. 64 (6): 602–9.  
  70. ^ Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L (2001). "The use of tetracyclines for the treatment of sarcoidosis". Arch Dermatol 137 (1): 69–73.  
  71. ^ El Sayed F, Dhaybi R, Ammoury A (2006). "Subcutaneous nodular sarcoidosis and systemic involvement successfully treated with doxycycline". J Med Liban 54 (1): 42–4.  
  72. ^ Briest W, Cooper TK, Tae HJ, Krawczyk M, McDonnell NB, Talan MI (2011). "Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of ehlers-danlos syndrome". J Pharmacol Exp Ther 337 (3): 621–27.  
  73. ^ "'"Antibiotics 'could help slow MS. BBC News. 11 December 2007. Retrieved 31 January 2008. 
  74. ^ Minagar, A.; Alexander, J. S.; Schwendimann, R. N.; Kelley, R. E.; Gonzalez-Toledo, E.; Jimenez, J. J.; Mauro, L.; Jy, W.; Smith, S. J. (2008). "Combination Therapy with Interferon Beta-1a and Doxycycline in Multiple Sclerosis: An Open-Label Trial". Archives of Neurology 65 (2): 199–204.  
  75. ^ Mishra GP, Mulani JD. "Doxycycline: An Old Drug With A New Role In Idiopathic Pulmonary Fibrosis". International Journal of Pharma and Bio Sciences. V1(2) 2010. ISSN 0975-6299.

External links

  • Patient Information Leaflet
  • Article on Doxycycline
  • U.S. National Library of Medicine: Drug Information Portal – Doxycycline
  • Research webpage of Mark Taylor who has pioneered the use of doxycycline as an antihelmintic
  • The Anti-Wolbachia Consortium uses drugs like doxycycline to treat parasitic diseases